Breast cancer Flashcards

1
Q

Non-mod risk factors for Breast cancer

A

Age
Ethnicity
Genetics (1 relative or p53 BRCA mutations)
Reproductive history (early menarche, age of first live birth, late menopause, parity)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Mod risk factors for breast cancer

A

Smoking
Alcohol
BMI (weight gain after age 18)
Radiation prior to age 30?

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Signs and symp of breast cancer

A
palpable mass
pain to breast area
nipple discharge
asymmetric thickening or nodularity
skin changes
unexplained weight loss and fatigue
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Types of breast cancer

A

Lobular carcinoma in situ
Ductal carcinoma in situ
Invasive lobulat carcinoma
Invasive ductal carcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

TMN staging

A

Tumor size
Nodal involvement
Metastatic disease (only in stage 4)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

ER/PR

A

estrogen progesterone receptors
anything greater than 1% is positive
can be treated with endocrine therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Oncotype DX test

A

prognostic: how likely to come bank
predicitive: how likely to benefit from chemo
<18 low risk
>30 high risk
Used in early-stage estrogen receptor + or DCIS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How to treat early stage noninvasive

A

LCIS: observation or remove
DCIS: remove +/- radiation, lymph node dissection not recommended

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Questions to ask treating invasive (3)?

A
  1. Hormone status?
  2. HER2 receptor status?
  3. Tumor size and node status?
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How to treat early stage invasive?

1A, 1B, 2A, 2B

A

goal=cure=5 yr surv

  1. Remove
  2. Radiation
  3. Systemic therapy either endocrine or targeted
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How to treat Stage 3 invasive?

A

Operable: Surgery +/- pre and post chemo
Inoperable: pre chemo, irradiation, post chemo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Tx for negative axillary noses, tumor>5 cm or positive margins

A

surgery, radiation, chemotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

ER+, HER2+

3

A

Endocrine therapy +/- chemotherapy with trastuzumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

ER+, HER2-

3

A

Endocrine therapy with chemotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

ER-, HER2+

3

A

+/- chemotherapy with trastuzumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

ER-, HER2-

3

A

Chemotherapy

17
Q

Tumor markers

A

Only important in metastatic cancer

CEA, CA 2729, Truquant BR, CA 15-3

18
Q

Preferred HER2-

A

Dose dense AC –> T
doxorubicin, cyclophosphamide, paclitaxel every 2 weeks
worried about cardiotoxicity
Must use growth factor

19
Q

Preferred HER2+

A

TCH +/- pertuzimab
TCH=docetaxel, carboplatin, trastuzumab +/- pertuzumab
worried about cardiotoxicity
Every 21 days for 6 cycles then continue only trastuzumab and pertuzumab every 21 days to complete 1 year

20
Q

For nausea

A

Fosaprepitant, dexameth, Zofran
PRN Compazine and Ativan
If failed: add olanzapine night before then 5 days after

21
Q

For myelosupression

A

Neulasta x1

or Neupogen x7

22
Q

Trastuzumab (Herceptin)

neo and meta

A

Binds to EGFR2
For HER2+
Load with 8 mg/kg then 6 mg/kg every 3 weeks for 1 yr.
Give after doxorubicin tx because of cardiotox
ECHO to check if EF>55%

23
Q

Pertuzumab (Perjeta)

neo and meta

A

HER2 dimerization inh used only with trastuzumab
For HER2+
Always a flat dose. Load then every 3 weeks. Cardiotox

24
Q

Neratinb (Nerlynx)

neo

A

Tyrosine kinase inhibitor. HER2 dimerization inh used only with trastuzumab after the 1 year of initial treatment.
Causes diarrhea, pre med with loperamide

25
Q

ado-trastuzumab
(Kadcyla)
meta

A

Drug conjugate for HER2+, every 3 weeks

detaches from tras once in cancer cell

26
Q

Lapatinib (tykerb)

A

Tyrosine kinase inhibitor (HER2 and EGFR)
oral
Hand and foot syndrome in combo with capecitabine

27
Q

HER2- ER+

metastatic treatment

A
Use with endocrine therapy
Cyclin-dep kinase inhibitors 
Palbociclib
Ribociclib
Abemaciclib
Causes: neutropenia, mucositis, headaches, n/v
28
Q

Anti-estrogens (3)

A

Tamoxifen
Toremifene
Raloxifene

29
Q

DOC in premenopausal, anti-est

A

Tamoxifen
SERM
blocks Est receptors in the breast but not other areas

OK to use in post-meno

30
Q

Tamoxifen properties

check is pt is on SSRIs!!

A

PO
Prodrug
Hot flashes (treat risk of clotting and endometrial cancer
interacts with 2d6 inh, 3a4 inh, warfarin

31
Q

LHRH agonists

A
ovary suppression
Goserelin
Leuprolide
Triptorelin
Use in high risk pre-menopausal with an aromatase inhibitor
32
Q

Aromatase inhibitors

A
Anastrazole
Letrozole
Exemestant
block estrogen in peripheral
use in high risk pre-meno
use in Post-meno because their ovaries don't produce
33
Q

Side effects of aromatase inhibitors

A

myalgias
osteoporosis
hot flashes
sex dysfunction

must start on Ca2+ and VitD
start denosumab

34
Q

Denosumab

A

every 6 months
binds to RANKL
increases bone mass in patients

35
Q

Antidepressants for hot flashes

A

Venlafaxine, citalopram, escitralopram

36
Q

Classes ok for hot flashes

A

non 2d6 antidepressants
gabapentin/pregabalin
clonidine